Table 1.
Target cancer antigens in head and neck cancer.
| Vaccine | Target antigens | Type | Phase | Identifier | Relevant references |
|---|---|---|---|---|---|
| Pre-active/active clinical trials | |||||
| ADXS11-001 | Human papillomavirus (HPV)16-E6/E7 | Viral Ag | Phase II | NCT02002182 | (136) |
| Phase I/II | NCT02291055 | N/A | |||
| DPX-E7 | HPV16-E7 | Viral Ag | Phase I/II | NCT02865135 | N/A |
| MEDI-0457 (INO-3112) | HPV16/18-E6/E7 | Viral Ag | Phase I/II | NCT03162224 | N/A |
| TG4001 | HPV16-E6/E7 | Viral Ag | Phase I/II | NCT03260023 | N/A |
| ISA101/101b | HPV16-E6/E7 | Viral Ag | Phase II | NCT02426892 | N/A |
| Phase II | NCT03258008 | N/A | |||
| ISA201 (Hespecta) | HPV16-E6/E7 | Viral Ag | Phase I | NCT02821494 | (121) |
| HARE-40 | HPV16-E6/E7 | Viral Ag | Phase I/II | NCT03418480 | N/A |
| Trojan | MAGE-A3 and HPV16-E7 | Viral Ag and tumour-associated antigen (TAA) | Phase I | NCT00257738 | (81) |
| MUC1 vaccine | MUC1 | TAA | Phase I/II | NCT02544880 | N/A |
| NANT | MUC1/CEA/HER2/Brachyury/Ras | TAA | Phase I/II | NCT03169764 | N/A |
| MVX-ONCO-1 | Allogeneic tumour-irradiated | Cellular | Phase II | NCT02999646 | N/A |
| AlloVax | Allogeneic tumour-chaperone-rich cell lysate | Cellular | Phase I/II | NCT01998542 | N/A |
| Phase II | NCT02624999 | N/A | |||
| Completed clinical trials | |||||
| Peptide pulsed dendritic cell | P53 | TAA | Phase I | NCT00404339 | (69) |
| Ras vaccine | Ras | TAA | Phase II | NCT00019331 | N/A |
| MEDI-0457 (INO-3112) | HPV16/18-E6/E7 | Viral Ag | Phase I/II | NCT02163057 | (111) |
| P16 vaccine | P16 | TAA | Phase I/II | NCT01462838 | (120) |
| Phase I | NCT02526316 | N/A | |||
| GI-6207 | CEA | TAA | Phase I | NCT00924092 | N/A |
| EBV vaccine | EBV | Viral Ag | Phase I | NCT01147991 | (58) |
| TRICOM-CEA(6D) | CEA | TAA | Phase I | NCT00027534 | N/A |
| Peptide with IFA | CDCA1, LY6K, and IMP3 | TAA | Phase I/II | UMIN000008379 | (87) |
| Survivin-2B vaccine | Survivin-2B | TAA | Phase I | UMIN000000976 | (70) |